VEGF Antibody (VG-1): sc-53462
- VEGF Antibody (VG-1) is a mouse monoclonal IgG1 κ, cited in 97 publications, provided at 200 µg/ml
- raised against recombinant VEGF189 of human origin
- Anti-VEGF Antibody (VG-1) is recommended for detection of 121, 165 and 189 VEGF isoforms of mouse, rat, human and canine origin by WB, IP, IF and IHC(P)
- Anti-VEGF Antibody (VG-1) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for VEGF Antibody (VG-1) for WB and IHC(P) applications. These reagents are now offered in bundles with VEGF Antibody (VG-1) (see ordering information below).
VEGF Antibody (VG-1) is a mouse monoclonal IgG1 kappa light chain antibody that detects vascular endothelial growth factor (VEGF) from mouse, rat, human, and canine samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-VEGF antibody (VG-1) is available in non-conjugated form and conjugated to agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® dyes. VEGF plays a crucial role in angiogenesis, forming new blood vessels to supply nutrients and oxygen to tissues during embryonic development and injury response. VEGF dysregulation contributes to various pathological conditions, including cancer, where VEGF promotes tumor growth and metastasis by enhancing blood supply to tumor microenvironments. VEGF exists in several isoforms, including VEGF121, VEGF165, and VEGF189, arising from alternative splicing with distinct biological activities and receptor binding affinities. VEGF165 represents the most abundant isoform, interacting with Flt-1 and KDR receptors to mediate endothelial cell proliferation and migration. VEGF′s role in stimulating angiogenesis makes VEGF a critical target for therapeutic interventions in cancer and diseases characterized by abnormal blood vessel growth.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
VEGF Antibody (VG-1) References:
- VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. | Greenberg, JI. and Cheresh, DA. 2009. Expert Opin Biol Ther. 9: 1347-56. PMID: 19761418
- VEGF in tumor progression and targeted therapy. | Chekhonin, VP., et al. 2013. Curr Cancer Drug Targets. 13: 423-43. PMID: 23167597
- VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. | Arcondéguy, T., et al. 2013. Nucleic Acids Res. 41: 7997-8010. PMID: 23851566
- RNA interference technology for anti-VEGF treatment. | Chen, S., et al. 2014. Expert Opin Drug Deliv. 11: 1471-80. PMID: 24898870
- VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications. | Alkharsah, KR. 2018. Int J Mol Sci. 19: PMID: 29865171
- Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. | Melincovici, CS., et al. 2018. Rom J Morphol Embryol. 59: 455-467. PMID: 30173249
- Targeting VEGF-neuropilin interactions: a promising antitumor strategy. | Peng, K., et al. 2019. Drug Discov Today. 24: 656-664. PMID: 30315890
- VEGF in Signaling and Disease: Beyond Discovery and Development. | Apte, RS., et al. 2019. Cell. 176: 1248-1264. PMID: 30849371
- Intravitreal anti-VEGF agents and cardiovascular risk. | Porta, M. and Striglia, E. 2020. Intern Emerg Med. 15: 199-210. PMID: 31848994
- VEGF overexpressed mesoangioblasts enhance urethral and vaginal recovery following simulated vaginal birth in rats. | Mori da Cunha, MGMC., et al. 2023. Sci Rep. 13: 8622. PMID: 37244975
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VEGF Antibody (VG-1) | sc-53462 | 200 µg/ml | $322.00 | |||
VEGF Antibody (VG-1): m-IgG Fc BP-HRP Bundle | sc-526815 | 200 µg Ab; 10 µg BP | $361.00 | |||
VEGF Antibody (VG-1): m-IgG1 BP-HRP Bundle | sc-532188 | 200 µg Ab; 20 µg BP | $361.00 | |||
VEGF Antibody (VG-1) AC | sc-53462 AC | 500 µg/ml, 25% agarose | $424.00 | |||
VEGF Antibody (VG-1) HRP | sc-53462 HRP | 200 µg/ml | $322.00 | |||
VEGF Antibody (VG-1) FITC | sc-53462 FITC | 200 µg/ml | $336.00 | |||
VEGF Antibody (VG-1) PE | sc-53462 PE | 200 µg/ml | $349.00 | |||
VEGF Antibody (VG-1) Alexa Fluor® 488 | sc-53462 AF488 | 200 µg/ml | $364.00 | |||
VEGF Antibody (VG-1) Alexa Fluor® 546 | sc-53462 AF546 | 200 µg/ml | $364.00 | |||
VEGF Antibody (VG-1) Alexa Fluor® 594 | sc-53462 AF594 | 200 µg/ml | $364.00 | |||
VEGF Antibody (VG-1) Alexa Fluor® 647 | sc-53462 AF647 | 200 µg/ml | $364.00 | |||
VEGF Antibody (VG-1) Alexa Fluor® 680 | sc-53462 AF680 | 200 µg/ml | $364.00 | |||
VEGF Antibody (VG-1) Alexa Fluor® 790 | sc-53462 AF790 | 200 µg/ml | $364.00 |